ABSTRACT
The nursing professional who treats critically ill children with cerebral injury is a key element within the pediatric intensive care team, since, through exhaustive assessment, plans nursing care in an integral manner aimed at the child and the family, and plays an essential role in the care of patients mainly at the hospital level (as well as at home). Therefore, the role played by nursing in the care of children with severe brain trauma is crucial. This guide offers nursing recommendations on neurocritical care, focusing on a systemic view based on nursing diagnoses according to the North American Nursing Diagnosis Association.
El profesional de enfermería que atiende a niños críticamente enfermos con lesión cerebral es un miembro clave dentro del equipo intensivista pediátrico, ya que, mediante la evaluación exhaustiva, planifica cuidados de enfermería de manera integral dirigidos al niño y a la familia. La enfermería como una profesión que entiende la salud de la persona humana desde una mirada integral cumple un rol esencial (indispensable) en el cuidado de los pacientes, principalmente, a nivel hospitalario (como domiciliario). Por ende, el rol que juega la enfermería en la atención de un niño con traumatismo encéfalocraneano grave es crucial en la gestión del cuidado infantil. Esta guía ofrece recomendaciones de enfermería sobre los cuidados neurocríticos focalizando una mirada sistémica basada en diagnósticos de enfermería según la Asociación Americana de Diagnósticos de Enfermería.
Subject(s)
Advanced Practice Nursing/standards , Brain Injuries, Traumatic/nursing , Consensus , Critical Care Nursing/standards , Advanced Practice Nursing/methods , Brain Injuries, Traumatic/etiology , Child , Critical Care/organization & administration , Critical Care Nursing/methods , Hospitalization , Humans , Intensive Care Units, PediatricABSTRACT
La Emergentología Pediátrica se ha desarrollado en el mundo como una subespecialidad de la pediatría durante las últimas décadas. Los registros muestran una creciente necesidad de sus servicios. Esta orientación tuvo su empuje inicial en Estados Unidos de América y nuestro país ha continuado por el mismo camino, así como muchos otros países latinoamericanos. Aun así, habrá que intensificar su promoción y trabajar en el desarrollo de la investigación y la docencia relacionadas con el área para promover el bienestar de los niños, sus familias y de la sociedad en general.
Pediatric Emergency Medicine has developed around the world as a subspecialty of pediatrics. There is plenty of data reflecting a growing need for its services. The subspecialty was initiated in the United States and Argentina, together with other Latin American countries, followed the same path. Nevertheless, there is yet much to be done. It is necessary to strengthen its promotion and to stimulate research and teaching activities in order to continue improving the quality of care delivered to the pediatric population, their families and society as a whole.
Subject(s)
Humans , Pediatrics , Emergency MedicineABSTRACT
Pediatric Emergency Medicine has developed around the world as a subspecialty of pediatrics. There is plenty of data reflecting a growing need for its services. The subspecialty was initiated in the United States and Argentina, together with other Latin American countries, followed the same path. Nevertheless, there is yet much to be done. It is necessary to strengthen its promotion and to stimulate research and teaching activities in order to continue improving the quality of care delivered to the pediatric population, their families and society as a whole.
La Emergentología Pediátrica se ha desarrollado en el mundo como una subespecialidad de la pediatría durante las últimas décadas. Los registros muestran una creciente necesidad de sus servicios. Esta orientación tuvo su empuje inicial en Estados Unidos de América y nuestro país ha continuado por el mismo camino, así como muchos otros países latinoamericanos. Aun así, habrá que intensificar su promoción y trabajar en el desarrollo de la investigación y la docencia relacionadas con el área para promover el bienestar de los niños, sus familias y de la sociedad en general.
Subject(s)
Pediatric Emergency Medicine/organization & administration , Quality of Health Care , Specialization , Child , Education, Medical/organization & administration , Humans , Pediatric Emergency Medicine/standardsABSTRACT
INTRODUCTION: Magnesium sulfate is a calcium antagonist that inhibits bronchial smooth muscle contraction promoting bronchodilation. It is used for the management of acute severe asthma in children; however most of the studies have been performed in adults. OBJECTIVE: To evaluate the effectiveness of intravenous magnesium sulfate for the treatment of pediatric patients with acute severe asthma exacerbations. POPULATION AND METHODS: A clinical, randomized, controlled trial was conducted between March 2006 and March 2011 at Hospital Universitario Austral. Children with acute severe asthma admitted to the emergency department were randomized into two groups. Group A (control group): standard protocol for the initial treatment of acute asthma exacerbation. Group B: treatment protocol with magnesium sulphate for acute severe asthma exacerbation. The primary outcome was the requirement of invasive or non invasive mechanical ventilation support. RESULTS: One hundred and forty three patients randomized into 2 groups were analyzed. The treatment group included 76 patients receiving magnesium sulfate within the first hour of the initiation of rescue treatment at the hospital, and the control group included 67 patients not treated with magnesium sulphate. Among the patients in the control group, 33% (n= 22) required mechanical ventilation support, compared to only 5% (n= 4) of the patients in the treatment group (p = 0.001). CONCLUSIONS: Intravenous infusion of magnesium sulfate during the first hour of hospitalization in patients with acute severe asthma significantly reduced the percentage of children who required mechanical ventilation support.
Subject(s)
Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Magnesium Sulfate/therapeutic use , Acute Disease , Adolescent , Child , Child, Preschool , Disease Progression , Female , Hospitals, University , Humans , Male , Respiration, Artificial , Tertiary Care CentersABSTRACT
Introduction. Magnesium sulfate is a calcium antagonist that inhibits bronchial smooth muscle contraction promoting bronchodilation. It is used for the management of acute severe asthma in children; however most of the studies have been performed in adults. Objective. To evaluate the effectiveness of intravenous magnesium sulfate for the treatment of pediatric patients with acute severe asthma exacerbations. Population and Methods. A clinical, randomized, controlled trial was conducted between March 2006 and March 2011 at Hospital Universitario Austral. Children with acute severe asthma admitted to the emergency department were randomized into two groups. Group A (control group): standard protocol for the initial treatment of acute asthma exacerbation. Group B: treatment protocol with magnesium sulphate for acute severe asthma exacerbation. The primary outcome was the requirement of invasive or non invasive mechanical ventilation support. Results. One hundred and forty three patients randomized into 2 groups were analyzed. The treatment group included 76 patients receiving magnesium sulfate within the first hour of the initiation of rescue treatment at the hospital, and the control group included 67 patients not treated with magnesium sulphate. Among the patients in the control group, 33% (n= 22) required mechanical ventilation support, compared to only 5% (n= 4) of the patients in the treatment group (p = 0.001). Conclusions. Intravenous infusion of magnesium sulfate during the first hour of hospitalization in patients with acute severe asthma significantly reduced the percentage of children who required mechanical ventilation support.
Introducción. El sulfato de magnesio es un antagonista del calcio que inhibe la contracción del músculo liso bronquial y favorece la broncodilatación. Se utiliza en el manejo del asma aguda grave en pediatría no obstante haber sido la mayoría de los estudios desarrollados en adultos. Objetivo. Evaluar la eficacia del sulfato de magnesio endovenoso para exacerbaciones graves de pacientes asmáticos pediátricos. Población y métodos. Se realizó un estudio clínico, controlado y aleatorizado, entre marzo de 2006 y marzo de 2011 en el Hospital Universitario Austral. Los pacientes con asma aguda grave admitidos en Emergencias se aleatorizaron en dos grupos. Grupo A: protocolo inicial estándar de exacerbación asmática aguda grave. Grupo B: protocolo de intervención con sulfato de magnesio de exacerbación asmática aguda grave. La variable principal de resultado fue la necesidad de soporte invasivo o no invasivo ventilatorio mecánico. Resultados. Se analizaron 143 pacientes aleatorizados en 2 grupos. El grupo de intervención de 76 pacientes que recibieron tratamiento con sulfato de magnesio dentro de la primera hora de iniciado el tratamiento de rescate en el hospital, y el grupo control testigo de 67 pacientes que no recibieron tratamiento con sulfato de magnesio. El 33% (n= 22) de los pacientes del grupo control requirió asistencia ventilatoria mecánica, en comparación con solo 4 (5%) de los pacientes del grupo intervención (p= 0,001). Conclusiones. El uso de sulfato de magnesio en infusión endovenosa en la primera hora de ingreso del paciente con asma aguda grave redujo significativamente el porcentaje de niños que requirieron asistencia ventilatoria mecánica.
Subject(s)
Adolescent , Child , Child, Preschool , Female , Humans , Male , Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Magnesium Sulfate/therapeutic use , Acute Disease , Disease Progression , Hospitals, University , Respiration, Artificial , Tertiary Care CentersABSTRACT
Introduction. Magnesium sulfate is a calcium antagonist that inhibits bronchial smooth muscle contraction promoting bronchodilation. It is used for the management of acute severe asthma in children; however most of the studies have been performed in adults. Objective. To evaluate the effectiveness of intravenous magnesium sulfate for the treatment of pediatric patients with acute severe asthma exacerbations. Population and Methods. A clinical, randomized, controlled trial was conducted between March 2006 and March 2011 at Hospital Universitario Austral. Children with acute severe asthma admitted to the emergency department were randomized into two groups. Group A (control group): standard protocol for the initial treatment of acute asthma exacerbation. Group B: treatment protocol with magnesium sulphate for acute severe asthma exacerbation. The primary outcome was the requirement of invasive or non invasive mechanical ventilation support. Results. One hundred and forty three patients randomized into 2 groups were analyzed. The treatment group included 76 patients receiving magnesium sulfate within the first hour of the initiation of rescue treatment at the hospital, and the control group included 67 patients not treated with magnesium sulphate. Among the patients in the control group, 33% (n= 22) required mechanical ventilation support, compared to only 5% (n= 4) of the patients in the treatment group (p = 0.001). Conclusions. Intravenous infusion of magnesium sulfate during the first hour of hospitalization in patients with acute severe asthma significantly reduced the percentage of children who required mechanical ventilation support.(AU)
Introducción. El sulfato de magnesio es un antagonista del calcio que inhibe la contracción del músculo liso bronquial y favorece la broncodilatación. Se utiliza en el manejo del asma aguda grave en pediatría no obstante haber sido la mayoría de los estudios desarrollados en adultos. Objetivo. Evaluar la eficacia del sulfato de magnesio endovenoso para exacerbaciones graves de pacientes asmáticos pediátricos. Población y métodos. Se realizó un estudio clínico, controlado y aleatorizado, entre marzo de 2006 y marzo de 2011 en el Hospital Universitario Austral. Los pacientes con asma aguda grave admitidos en Emergencias se aleatorizaron en dos grupos. Grupo A: protocolo inicial estándar de exacerbación asmática aguda grave. Grupo B: protocolo de intervención con sulfato de magnesio de exacerbación asmática aguda grave. La variable principal de resultado fue la necesidad de soporte invasivo o no invasivo ventilatorio mecánico. Resultados. Se analizaron 143 pacientes aleatorizados en 2 grupos. El grupo de intervención de 76 pacientes que recibieron tratamiento con sulfato de magnesio dentro de la primera hora de iniciado el tratamiento de rescate en el hospital, y el grupo control testigo de 67 pacientes que no recibieron tratamiento con sulfato de magnesio. El 33% (n= 22) de los pacientes del grupo control requirió asistencia ventilatoria mecánica, en comparación con solo 4 (5%) de los pacientes del grupo intervención (p= 0,001). Conclusiones. El uso de sulfato de magnesio en infusión endovenosa en la primera hora de ingreso del paciente con asma aguda grave redujo significativamente el porcentaje de niños que requirieron asistencia ventilatoria mecánica.(AU)
